The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma
Sarah A Holstein 1, Nizar Bahlis 2, P Leif Bergsagel 3, Manisha Bhutani 4, Niccolo Bolli 5, Carrie Brownstein 6, Pierre Demolis 7, David Foureau 4, Francesca Gay 8, Irene M Ghobrial 9, Nicole Gormley 10, Jens Hillengass 11, Martin Kaiser 12, Marcela V Maus 13, J Joseph Melenhorst 14, Maximilian Merz 15, Michael O Dwyer 16, Bruno Paiva 17, Marcelo C Pasquini 18, Nina Shah 19, Sandy W Wong 19, Saad Z Usmani 4, Philip L McCarthy 11
The fifth annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma was conducted as one of the American Society of Hematology Annual Meeting Scientific Workshops on Thursday December 3, 2020.
This workshop focused on four main topics: (1) integrating minimal residual disease into clinical trial design and practice; (2) the molecular and immunobiology of disease evolution and progression in myeloma; (3) adaptation of next-generation sequencing, next-generation flow cytometry, and cytometry by time of flight techniques; and (4) chimeric antigen receptor T-cell and other cellular therapies for myeloma. In this report, we provide a summary of the workshop presentations and discuss future directions in the field.
Keywords: CAR T-cell; Cellular therapy; Endpoint; Immune profiling; Minimal residual disease; Multiple myeloma.
CITA DEL ARTICULO Transplant Cell Ther. 2021 Oct;27(10):807-816. doi: 10.1016/j.jtct.2021.05.027. Epub 2021 Jun 6.